Why the study?
Does aliskiren improve cardiac end-organ protection compared to ACE inhibitors and ARBs in spontaneously hypertensive rats?
Population
Spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) controls
Comparison
Aliskiren via osmotic minipump for 1-3 weeks vs Vehicle, captopril, or irbesartan via osmotic…
Design
Preclinical
Follow-up
1-3 weeks
Authors
Loading...
Supports aliskiren evaluation for hypertensive cardiac remodeling; leaves open human translation versus ACEi/ARBs.
Does aliskiren improve cardiac end-organ protection compared to ACE inhibitors and ARBs in spontaneously hypertensive rats?
In a hypertensive rat model, aliskiren provides comparable cardiac hypertrophy reduction and endothelial function improvement to ACEi/ARBs, with superior long-term cardiac angiotensin suppression.
Esch et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: